TL1A-Linked Immune Remodeling Emerges in Crohn’s Perianal Fistulising Disease
Rectal tissue from patients with Crohn’s disease and perianal fistulising disease shows a distinct cellular imprint that does not simply track with luminal inflammation. In this study, investigators profiled rectal biopsies from 31 patients with Crohn’s disease, with and without perianal fistulising disease, using single-cell RNA sequencing and then pushed the findings into functional systems built from peripheral CD3+ T cells, intestinal explants, primary fibroblasts, and epithelial monolayers. The result is a tissue-level map of how fistula-prone disease may begin before a tract is fully established.
The central signal points to TL1A activation in CD4+ T cells. In that setting, the rectal mucosa becomes biologically remodeled in a way that appears specific to the fistulising phenotype rather than a generic reflection of bowel inflammation. The tissue changes are not subtle housekeeping shifts; they include fibroblast expansion, induction of matrix-degrading enzymes, and transcriptomic changes in stromal and epithelial compartments that fit with a mucosa being pushed toward invasion, tissue turnover, and immune activation.
Fibroblasts and Epithelium Respond to a Shared Inflammatory Circuit
A striking feature of the data is the division of labor between stromal and epithelial compartments. Downstream of TL1A, lymphotoxin beta — or its functional heterotrimer LTα1β2 — emerged as a novel mediator acting on rectal fibroblasts. In parallel, IL-22 drove a related program in epithelial cells. The fibroblast response included an increased abundance of these cells and a transcriptomic rewiring of lamina propria S1 fibroblasts, a pattern consistent with stromal activation and matrix remodeling. The epithelial arm was marked by antibacterial and immune-response signatures, suggesting that the mucosal surface itself is being instructed to behave differently in the face of persistent immune pressure.
One sentence captures the clinical weight of the finding: the rectal mucosa is not passively inflamed; it is being actively reprogrammed.
The biology matters because fistula formation depends on more than cytokine excess. Tissue invasion requires altered barrier behavior, activated mesenchymal support cells, and enzymes capable of remodeling the extracellular matrix. By identifying LTα1β2 and IL-22 as downstream products of TL1A activation, the study places these pathways in a mechanistic sequence that can plausibly connect adaptive immune activation to structural disease in the perianal region.
A Pathway That Persists Beyond TNF Blockade
The most clinically relevant part of the study is the independence from TNF signaling. Induction of LTα1β2 and IL-22 occurred without reliance on TNF, meaning the TL1A-linked circuit can remain active even when TNF is pharmacologically suppressed. For a disease often treated with anti-TNF therapy, that observation carries real bedside consequence. Persistent fistulising disease despite TNF blockade has long suggested that another inflammatory driver is still operating in the background, and this work identifies one plausible candidate.
This is where the molecular story becomes therapeutically important. If TL1A sits upstream of a fibroblast- and epithelium-activating axis that survives anti-TNF treatment, then ongoing tissue injury in perianal Crohn’s disease may be explained by a pathway not fully addressed by current standard biologics. The study does not claim clinical efficacy for TL1A inhibition. It does, however, provide a biologically coherent reason to examine it as a therapeutic target in fistulising disease.
What the Rectal Biopsies Add to the Disease Model
Rectal biopsies offer a window into the local tissue environment where fistula-prone biology is likely being shaped. In this cohort, the rectal mucosa of patients with Crohn’s disease and perianal fistulising disease carried cellular and transcriptomic changes that were specific to the fistulising phenotype and independent of luminal inflammation. That separation is important because it argues against reducing perianal disease to an extension of generic mucosal activity in the gut lumen.
Instead, the data suggest a compartmentalized mucosal program. CD4+ T cells appear to be activated in a way that engages TL1A signaling, which then propagates to fibroblasts through LTβ-related signaling and to epithelial cells through IL-22. Fibroblasts expand and express matrix-degrading machinery. Epithelial cells mount antibacterial and immune-response programs. The combined effect is a rectal microenvironment primed for structural remodeling rather than restoration of tissue homeostasis.
Why This Matters for Perianal Crohn’s Disease Research
Perianal fistulising disease affects about 20% of patients with Crohn’s disease, yet its aetiology remains unknown. That gap has made the condition especially frustrating in practice, because treatment failure often reflects incomplete understanding of the tissue biology driving fistula persistence. By linking TL1A-activated T cells to a rectal mucosal signature that includes stromal expansion, matrix remodeling, and epithelial immune activation, this study offers a framework for understanding why perianal disease can remain so difficult to control.
The findings also create a sharper experimental agenda. Future work will need to determine whether the TL1A-LTα1β2/IL-22 axis is a cause of fistula development, a sustaining mechanism, or both. It will also need to test how this pathway behaves across disease duration, how it relates to clinical severity, and whether inhibition of TL1A can reverse the stromal and epithelial programs already established in rectal tissue. For now, the evidence points to a distinct mucosal circuit that may help explain why anti-TNF therapy is not enough for many patients with perianal fistulising Crohn’s disease.
The study closes one mechanistic loop and opens another. Rectal tissue in fistulising Crohn’s disease carries a programmed inflammatory signature, and TL1A now sits at the center of it.